Lung Cancer

PET with fludeoxyglucose/computed tomography (FDG PET/CT) is widely used in pretreatment and posttreatment evaluations of various types of cancer, including non–small cell lung cancer. This issue of PET Clinics addresses the serious ongoing health problem of non–small cell lung cancer. The staging article summarizes the changes to TNM classification of lung cancer that have recently[…]

Treatment Planning for Radiation Therapy

PET scanning plays key roles in planning the management of patients with lung cancer who are candidates for curative-intent treatment with radiotherapy and has contributed to improvements in survival. 18F-fluorodeoxyglucose–PET is the most important modality for staging, patient selection, and radiotherapy target volume definition in patients with unresectable non–small cell lung cancer. Developments include the[…]

Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment

Significant advances in understanding the genomic landscape of non–small cell lung cancer (NSCLC) together with the coupling discovery of key oncogenic drivers and the development of effective targeted and immunotherapeutic agents have revolutionized the management of this malignancy. Although these therapies have resulted in improved outcomes for a subgroup of patients, their benefit may not[…]

18F-Fluoro-2-Deoxy-d-Glucose PET/Computed Tomography Evaluation of Lung Cancer in Populations with High Prevalence of Tuberculosis and Other Granulomatous Disease

Pulmonary tuberculosis infects one-third of world’s population and is responsible for the high mortality and morbidity in developing countries. The presence of a high number of macrophages and lymphocytes in active tuberculosis granulomas is associated with high uptake of 18F-fluoro-2-deoxy-d-glucose on PET imaging mimicking lung cancer. In many cases, radiological features of pulmonary tuberculosis are[…]

Lung Neoplasms with Low F18-Fluorodeoxyglucose Avidity

Some malignant lung neoplasms may demonstrate low or absent uptake on F18-fluorodeoxyglucose (FDG) PET/computed tomography. Pathologic type and clinical stage are independent factors associated with FDG avidity. Among lung malignancies with low FDG avidity, adenocarcinoma in situ and carcinoid are the most common. Early stage disease often has low FDG uptake. Small lesion size is[…]